Teduglutide treatment prevents PCs loss caused by GVHD in mice. (A) Representative immunohistochemistry staining for the PC marker, lysozyme (red), in small intestine from allo-HCT BALB/c mice on day 10. Mice treated with vehicle or teduglutide were compared with untreated controls. Mice were treated with teduglutide or vehicle from day −3 until day +3 unless differently specified. Scale bars, 50 to 100 μm. (B) Quantification of PCs/crypt of untreated BALB/c mice (n = 5) or from allo-HCT BALB/c mice on day 10 treated with vehicle or teduglutide (n = 8 per group). Results were pooled from 2 independent experiments. The P values were calculated using the unpaired, 2-sided Student t test. (C-E) qPCR-based quantification of lysozyme, Reg3γ, and Defα-4 expression in small intestine from untreated or allo-HCT BALB/c mice on day 5 treated with vehicle or teduglutide (n = 11 per group). Data were pooled from 2 independent experiments. The P values were calculated using the unpaired, 2-sided Student t test. (F) Volcano plot shows the top 25 regulated genes in BALB/c mice with GVHD on day 10 post–allo-HCT that were treated with teduglutide from day −3 to day +10 and relative to the vehicle-treated group. The experiment was performed once. (G) Gene-expression array indicates the top 10 positive regulated genes involved in response to gram-positive bacterium within the teduglutide-treated mice in comparison with the GVHD group. Mice were treated with teduglutide or vehicle from day −3 to day +10. The experiment was performed once. *Nonadjusted value of P < .05.